Provided by Tiger Trade Technology Pte. Ltd.

BioAtla, Inc.

0.1532
-0.0168-9.88%
Post-market: 0.1514-0.0018-1.17%18:12 EDT
Volume:821.37K
Turnover:129.38K
Market Cap:12.69M
PE:-0.13
High:0.1690
Open:0.1560
Low:0.1506
Close:0.1700
52wk High:1.43
52wk Low:0.1300
Shares:82.85M
Float Shares:69.15M
Volume Ratio:0.70
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1495
EPS(LYR):-1.4365
ROE:-813.88%
ROA:-105.08%
PB:-0.41
PE(LYR):-0.11

Loading ...

Bioatla and Gatc Health Announce a $40 Million Special Purpose Vehicle (Spv) Transaction to Advance Ozuriftamab Vedotin (Oz-V) Into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (Opscc)

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: to Retain 65% Ownership of Oz-V Across All Solid Tumor Indications After Completion of Spv Transaction

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: Phase 3 Trial Execution for Oz-V Enrollment Anticipated to Begin Early 2026

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: Co & Gatc Health to Collaborate With Inversagen AI for Research and Development of Cab Senolytic Therapies

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: Will Lead Phase 3 Trial Execution for Oz-V in Opscc Through Data Readout for Potential Accelerated Approval

THOMSON REUTERS
·
Dec 31, 2025

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

GlobeNewswire
·
Dec 31, 2025

BioAtla Inc. Held Special Shareholder Meeting

Reuters
·
Dec 31, 2025

BioAtla Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Nov 25, 2025

BioAtla Secures $7.5 Million Pre-Paid Advance Financing from Yorkville and Anson Funds

Reuters
·
Nov 21, 2025

BioAtla Agrees to $22.5 Million in Financing Agreements

MT Newswires Live
·
Nov 21, 2025

Bioatla Enters Into Agreements for up to $22.5 Million Flexible Financing

THOMSON REUTERS
·
Nov 21, 2025

Press Release: BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

Dow Jones
·
Nov 21, 2025

BioAtla Q3 Net Income USD -15.778 Million

Reuters
·
Nov 20, 2025

BioAtla’s Strategic Advancements and Promising Clinical Data Drive Buy Rating

TIPRANKS
·
Nov 16, 2025

BioAtla Q3 net loss widens to $15.8 mln

Reuters
·
Nov 14, 2025

BioAtla Q3 EPS $(0.27) Beats $(0.30) Estimate

Benzinga
·
Nov 14, 2025

BRIEF-BioAtla Q3 Net Income USD -15.778 Million

Reuters
·
Nov 14, 2025

BioAtla announces data on Mecbotamab Vedotin

TIPRANKS
·
Nov 07, 2025

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

GlobeNewswire
·
Nov 07, 2025

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

GlobeNewswire
·
Nov 05, 2025